Literature DB >> 14614208

Trial to predict malignancy of affected parathyroid glands in primary hyperparathyroidism.

Qingxiang Chen1, Hiroshi Kaji, Rikako Nomura, Hideaki Sowa, Mika Yamauchi, Tatsuo Tsukamoto, Toru Yamaguchi, Akira Kobayashi, Toshitsugu Sugimoto, Kazuo Chihara.   

Abstract

Parathyroid cancer is rare but relatively frequent in Japan compared to Western countries. Surgical parathyroidectomy is the primary choice for radical treatment of primary hyperparathyroidism (pHPT), hence it is important to distinguish malignant from benign tumor in the determination of surgical indication as well as method of operation. However, it is not easy to diagnose parathyroid cancer prior to operation. In the present study, we analyzed the background data, biochemical data and bone mineral density (BMD) of 131 patients with pHPT (111 benign and 20 malignant). BMD of the lumbar spine and mid-radius was measured by dual-energy X-ray absorptiometry. Serum levels of calcium, alkaline phosphatase (ALP), and parathyroid hormone (PTH) were significantly higher in malignant group compared to benign one. The extent of elevation of mid PTH seemed to be higher than that of intact PTH in malignant group. Age-, gender-, and race-adjusted BMD of distal one-third of radius was significantly decreased in malignant group compared to benign one, although that of lumbar spine was not significantly different between the two groups, indicating that osteopenia was marked in the region which was rich in cortical bone in malignant group. On the other hand, serum levels of calcium, ALP, and mid PTH as well as age were selected as predictors of malignancy in univariate logistic regression analysis, while serum level of intact PTH was not selected. In conclusion, radial BMD was lower in malignant group compared to benign one in pHPT. Serum levels of calcium, ALP and mid PTH were useful to predict malignancy of affected parathyroid glands in pHPT patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14614208     DOI: 10.1507/endocrj.50.527

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  [Prophylactic parathyroidectomy for familial parathyroid carcinoma].

Authors:  O Gimm; K Lorenz; P Nguyen Thanh; U Schneyer; M Bloching; V M Howell; D J Marsh; B T Teh; U Krause; H Dralle
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

2.  Severe Hyperparathyroidism Versus Parathyroid Carcinoma: A clinical dilemma.

Authors:  Mariam Al-Fadhli; Suhail A R Doi; Thomas Muttikkal; Basel Al-Sumait
Journal:  Sultan Qaboos Univ Med J       Date:  2010-04-17

3.  Parathyroid carcinoma: A rare case with mandibular brown tumor.

Authors:  Payam S Pahlavan; Marianne C Severin
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

4.  Differential findings of tc-99m sestamibi dual-phase parathyroid scintigraphy between benign and malignant parathyroid lesions in patients with primary hyperparathyroidism.

Authors:  Miju Cheon; Joon Young Choi; Jae-Hoon Chung; Ji Young Lee; Sook Kyung Cho; Jang Yoo; Soo Bin Park; Kyung-Han Lee; Byung-Tae Kim
Journal:  Nucl Med Mol Imaging       Date:  2011-08-19

5.  Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism.

Authors:  Jae Hyun Bae; Hyung Jin Choi; Yenna Lee; Min Kyong Moon; Young Joo Park; Chan Soo Shin; Do Jun Park; Hak Chul Jang; Seong Yeon Kim; Sang Wan Kim
Journal:  J Korean Med Sci       Date:  2012-07-25       Impact factor: 2.153

6.  Intrathyroidal Parathyroid Carcinoma Presenting as Asymptomatic High Normal Serum Calcium and Slightly Elevated Intact Parathyroid Hormone: A Case Report and Review of Literature.

Authors:  Benjamin Quartey; Craig Shriver; Daniel Russell
Journal:  World J Oncol       Date:  2011-06-08

Review 7.  Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma.

Authors:  Luís Cardoso; Mark Stevenson; Rajesh V Thakker
Journal:  Hum Mutat       Date:  2017-09-25       Impact factor: 4.878

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.